Glox Therapeutics, a company developing precision antibiotic therapies based on naturally occurring bacteriocins, has raised £4.3m in seed funding to develop targeted therapeutics against antibiotic-resistant Gram-negative bacteria.
The US Centers for Disease Control and Prevention (CDC) says COVID-19 has ‘pushed back years of progress’ in combating antimicrobial resistance (AR) in the US – adding that the threat from AR has also got worse.
Moderna and the International Vaccine Institute (IVI) have signed a Memorandum of Understanding (MOU) to establish a partnership for vaccine research and development.
Releasing its first-ever report on the pipeline of vaccines in development to prevent infections caused by antimicrobial-resistant (AMR) bacterial pathogens, the WHO is calling for more AMR vaccine development.
A well-funded and appropriately rewarded biotech ecosystem is needed for the next generation of antibacterials to reach the clinic and beyond, according to BIO’s State of Innovation in Antibacterial Therapeutics report.
